Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Relay Therapeutics's share price for the quarter that ended in Dec. 2023 was $11.01. Relay Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 127.46 Mil. Therefore, Relay Therapeutics's market cap for the quarter that ended in Dec. 2023 was $1,403.36 Mil.
Relay Therapeutics's quarterly market cap
declined
from Jun. 2023 ($1,531.63 Mil) to Sep. 2023 ($1,035.78 Mil) but then
increased
from Sep. 2023 ($1,035.78 Mil) to Dec. 2023 ($1,403.36 Mil).
Relay Therapeutics's annual market cap
declined
from Dec. 2021 ($3,323.13 Mil) to Dec. 2022 ($1,809.41 Mil) and
declined
from Dec. 2022 ($1,809.41 Mil) to Dec. 2023 ($1,403.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Relay Therapeutics's Enterprise Value for Today is $237.20 Mil.
Relay Therapeutics Market Cap Historical Data
The historical data trend for Relay Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Relay Therapeutics's Market Cap
For the Biotechnology subindustry, Relay Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relay Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's Market Cap falls into.
Relay Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Relay Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics (NAS:RLAY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Relay Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Relay Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Relay Therapeutics (Relay Therapeutics) Business Description
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RLAY has been successfully added to your 